Delivery Order SPE2DB20D1100-SPE2DB25FE1JL
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $2,098.25 to AmerisourceBergen Drug Corp for VENCLEXTA Starting Pack UD UU 42S on July 21, 2025, with an ultimate completion date of August 11, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.9 billion prime vendor agreement running through December...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for VENCLEXTA 100 mg tablets (120 count units) valued at $9,728.17, with an ultimate completion date of June 24, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded to the Conshohocken, Pennsylvania-based pharmaceutical distributor. The award represents a child order under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a $2,289.70 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Venclexta 100 mg tablets (28-count unit dosage). This non-set-aside competitive award is scheduled for completion by September 30, 2025, with performance at the contractor's facility in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a...
- The Defense Logistics Agency awarded a $4,579.40 firm fixed-price delivery order to AmerisourceBergen Drug Corp for VENCLEXTA 100 mg tablets (28-count units) on July 30, 2025, with an ultimate completion date of August 20, 2025. The contract carries no set-aside designation, indicating it was competitively awarded. Performance of this delivery order is based in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order represents a child...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $9,728.17 on June 16, 2025, for the supply of Venclexta 100 mg tablets (120-count units). This competitively awarded, firm fixed-price contract carries an ultimate completion date of July 9, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $19,456.34 to AmerisourceBergen Drug Corp for VENCLEXTA 100 MG tablets (120-count units) with a firm fixed price structure. This non-set-aside contract was competitively awarded on June 3, 2025, with an ultimate completion date of June 25, 2025. The award represents a child delivery order under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $1 billion comprehensive...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Venclexta 100 mg tablets (120-count units) valued at $9,728.17, with an ultimate completion date of October 8, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a Delivery Order valued at $19,456.34 to AmerisourceBergen Drug Corp for 120 tablets of Venclexta 100 mg, a pharmaceutical product for blood cancer treatment. Issued on August 13, 2025, with an ultimate completion date of September 4, 2025, this firm fixed-price contract represents a non-competitive award to the established vendor. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, where the company maintains...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Venclexta 100 mg tablets in quantities of 120 units. This firm fixed price delivery order, valued at $58,369.02, represents a non-competitive, non-set-aside award and is scheduled for completion by August 14, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, fulfills this order from its...
- The Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of VENCLEXTA 100 mg tablets (120 count), valued at $9,728.17. This firm fixed-price, competitively awarded delivery order is expected to be completed by August 14, 2025, with performance to be executed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award carries no set-aside designation, reflecting the company's demonstrated...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FE1JLDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $2,098.25 to AmerisourceBergen Drug Corp for VENCLEXTA Starting Pack UD UU 42S, a pharmaceutical product for federal medical procurement. This firm fixed-price delivery order, issued on September 26, 2025, with an ultimate completion date of October 20, 2025, represents a non-set-aside competitive award to the Conshohocken, Pennsylvania-based pharmaceutical distributor. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX, which is valued at $999,999,999.00 and extends through December 2026, serving as a comprehensive global pharmaceutical support vehicle for military healthcare programs. AmerisourceBergen Drug Corp functions as a critical vendor within the Defense Logistics Agency's Medical Supply Chain, supplying a comprehensive range of pharmaceutical products and medical supplies including brand-name and generic medications, vaccines, and specialized healthcare commodities across multiple therapeutic domains. The company's extensive federal contract portfolio demonstrates its capability to fulfill diverse medical procurement requirements through open competition, supporting the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. This particular delivery order for VENCLEXTA, a leukemia treatment medication, exemplifies the company's role in supporting military and federal healthcare systems with specialized pharmaceutical products necessary for patient care across the armed forces and veteran populations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.1k | 9/26/25 |